Candel Therapeutics

Our Chief Scientific Officer, Francesca Barone, is presenting at #IOVC2026 in Iceland on April 27th on aglatimagene besadenovec (CAN-2409), our locally delivered viral immunotherapy for solid tumors. candeltx.com @baroneExpMed $CADL

We’re heading to #AUA2026 in Washington, D.C.! Join us for our presentation featuring the phase 3 trial of aglatimagene besadenovec in localized prostate cancer on May 15 at 11:30 AM and visit our booth. ir.candeltx.com/news-releases/… #ProstateCancer #Immunotherapy $CADL

@ParadeMagazine recently featured Kyle Donahue’s remarkable story of her five-year journey with #glioblastoma and her experience in our phase 1b clinical trial of linoserpaturev (CAN-3110). parade.com/health/kyle-do… #ClinicalResearch #PatientStory #Immunotherapy $CADL

Our CEO, @paulpetertak, shares his perspective in @PharmaTechFocus on the shift toward targeted therapies in oncology and where viral immunotherapies fit in. pharmaceutical-technology.com/features/targe… #Immunotherapy #Oncology $CADL

April is #CancerControlMonth. At Candel, we’re advancing multimodal viral immunotherapies aglatimagene besadenovec in prostate & lung cancer, and linoserpaturev in recurrent glioblastoma, working to bring new options to patients. #CancerResearch #Immunotherapy

Extended follow-up data from our phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer will be presented at #AUA2026 in Washington, D.C. ir.candeltx.com/news-releases/… @AmerUrological #AUA2026 #ProstateCancer #Immunotherapy $CADL

On #WorldHealthDay, we reaffirm our commitment to the power of science to transform cancer care. At Candel, we’re advancing a pipeline of multimodal viral immunotherapies designed to harness the immune system to fight cancer and bring new options within reach for patients.

@TargetedOnc covered our latest aglatimagene besadenovec (CAN-2409) data in ICI-resistant advanced NSCLC: 50% alive at 24 months, 35% at 30 months, 13% beyond 50 months. Persistence of a long-term survival tail in this difficult-to-treat population. targetedonc.com/view/aglatimag…

This #DoctorsDay, we thank the physicians, researchers, and clinical investigators who dedicate their lives to advancing cancer care and improving patient outcomes. Your expertise, compassion, and commitment drive our shared mission to develop new treatment options.

Our enLIGHTEN™ Discovery Platform is an AI-driven platform leveraging human biology and advanced analytics to create new HSV-based viral immunotherapies for solid tumors. Learn more: candeltx.com/platforms/ #Immunotherapy #AI $CADL

Our CEO, @paulpetertak, discusses linoserpaturev (CAN-3110) on the Leading Beyond The Lab podcast, sharing the story of a recurrent glioblastoma patient who, five years after a single injection, is living a normal life with continued tumor shrinkage. $CADL #Glioblastoma

#DYK Our phase 3 trial of aglatimagene besadenovec (CAN-2409) in localized prostate cancer showed statistically significant improvement in prostate cancer-specific disease-free survival. We plan to submit a BLA in Q4 2026. #ProstateCancer #Immunotherapy $CADL

We announced updated survival data from our phase 2a trial of aglatimagene besadenovec (CAN-2409) in advanced NSCLC patients with inadequate response to ICI treatment. Read the full announcement: ir.candeltx.com/news-releases/… #NSCLC #Immunotherapy

We announced our Q4 2025 and full year 2025 financial results and recent corporate highlights, including updates on the aglatimagene besadenovec (CAN-2409) and linoserpaturev (CAN-3110) programs. Read here: ir.candeltx.com/news-releases/… #Immunotherapy $CADL

Fierce covered our $100M royalty financing agreement with RTW Investments to support the potential U.S. launch of aglatimagene besadenovec (CAN-2409) for localized prostate cancer, pending FDA approval. We remain on track to submit our BLA in Q4 2026. fiercebiotech.com/biotech/candel…

This @cure_today article explores linoserpaturev (CAN-3110), our viral immunotherapy candidate for recurrent glioblastoma, through the story of Kyle Donahue, a five-year survivor. curetoday.com/view/given-mon… #Glioblastoma #Immunotherapy

Our CEO, Dr. @paulpetertak, will present at the TD Cowen Health Care Conference this week. Highlighting Candel's progress in developing off-the-shelf multimodal immunotherapies, including aglatimagene besadenovec (CAN-2409) and linoserpaturev (CAN-3110). ir.candeltx.com/news-releases/…

Results from our aglatimagene besadenovec (CAN-2409) program in advanced lung cancer, presented at IASLC 2025. In unresectable stage III/IV NSCLC patients with an inadequate response to ICI, median OS was 24.5 mo (25.4 mo in nonsquamous histology). ascopost.com/news/september…

This article explores how aglatimagene besadenovec (CAN-2409) works to create systemic tumor-specific immune surveillance and a durable anti-tumor response. Learn about the science behind our viral immunotherapy approach and what it means for patients. nature.com/articles/d4374…

Our CEO, @paulpetertak, M.D., Ph.D., FMedSci, was featured on the Leading Beyond The Lab podcast.  Thank you ARTO Talent for a great conversation!  $CADL